WebApr 29, 2024 · Deucravacitinib meets primary end points for treating moderate to severe psoriasis. In 2 recent phase 3 trials, deucravacitinib (BMS-986165, Bristol Myers Squibb [BMS]), demonstrated progress toward becoming a new treatment for moderate to severe plaque psoriasis. 1,2. Deucravacitinib is the first and only tyrosine kinase 2 (TYK2) … WebNov 11, 2024 · To assess the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in a phase II trial in adult patients with active systemic lupus erythematosus (SLE). Methods. Adults with active SLE were enrolled from 162 sites in …
Deucravacitinib in Moderate to Severe Psoriasis: Clinical …
WebNov 3, 2024 · Deucravacitinib is being studied in a wide spectrum of immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus and inflammatory bowel disease. … WebDeucravacitinib is being developed by Bristol Myers Squibb for the treatment of multiple immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus and inflammatory bowel disease. contractors in batangas
Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) …
WebApr 10, 2024 · Background The objective of this post-hoc analysis was to assess the efficacy and safety of upadacitinib in psoriatic arthritis (PsA) patients with axial involvement. Methods Post-hoc analysis of SELECT-PsA 1 and SELECT-PsA 2 in patients randomized to upadacitinib 15 mg (UPA15), placebo (switched to UPA15 at week 24), or … WebResults from the initial 16-week, placebo (PBO)-controlled period (Part A) of a 52-week, blinded phase 2 trial in PsA showed that DEUC was significantly more efficacious than PBO. 1 The Psoriatic Arthritis Disease Activity … WebApr 10, 2024 · The study consisted of pooled analyses of the phase 3 reSURFACE 1 (ClinicalTrials.gov Identifier: NCT01722331) ... 2 inhibitor deucravacitinib. 3 The study … contractors in batesville ms